Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor. Comput. Struct. Biotechnol. J., (19):3674--3681, Elsevier BV, June 2021. [PUMA: Binding Crizotinib Drug LRRK2 Protein-ligand Structure-based interactions repositioning screening site zno]